IPO - Tarsus Pharmaceuticals, Inc.

Form Type: 8-K

Filing Date: 2025-03-18

Corporate Action: Ipo

Type: New

Accession Number: 000181979025000035

Filing Summary: Tarsus Pharmaceuticals, Inc. disclosed the completion of an offering of shares under an Underwriting Agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc., and Barclays Capital Inc. The offering involved the sale of 2,808,988 shares of common stock at a public offering price of $44.50 per share. The Underwriters purchased the shares at $41.83 per share, and an option was exercised to purchase an additional 421,348 shares at the same price. The total number of shares sold, including the additional shares, reached 3,230,336. The net proceeds from the offering amounted to approximately $134.8 million after deductions for underwriting discounts and offering expenses.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-03-13

Corporate Action: Ipo

Type: New

Accession Number: 000119312525053978

Filing Summary: On March 12, 2025, Tarsus Pharmaceuticals, Inc. entered into an Underwriting Agreement with Goldman Sachs & Co. LLC, BofA Securities, Inc., and Barclays Capital Inc. for the sale of 2,808,988 shares of the Company's common stock at a public offering price of $44.50 per share. The Underwriters agreed to purchase the shares for $41.83 per share, providing the Company with expected net proceeds of approximately $117.1 million, assuming no additional shares are purchased under the Underwriters' 30-day option. The Offering is expected to close on March 14, 2025. The Offering is conducted under the Company's shelf registration statement on Form S-3, and two press releases were issued regarding a proposed offering of $100.0 million and an upsized offering of $125.0 million, reflecting the size adjustments made to the offering. Legal opinions relevant to the offering were also included in the attachments. Forward-looking statements highlight risks related to the closing and proceeds from the offering.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-03-12

Corporate Action: Ipo

Type: New

Accession Number: 000119312525052954

Filing Summary: Tarsus Pharmaceuticals, Inc. is conducting an initial public offering of shares of its common stock, targeting a total offering amount of $100 million. The common stock, listed under the symbol 'TARS' on the Nasdaq Global Select Market, had a last reported sale price of $47.15 per share on March 11, 2025. The company aims to use the proceeds from this offering for the commercialization of its FDA-approved treatment for Demodex blepharitis, called XDEMVY, as well as for advancing its product pipeline, including TP-04 for Ocular Rosacea and TP-05 for Lyme disease prophylaxis. There is an underwriters' option to purchase an additional $15 million worth of shares. The company was incorporated on November 17, 2016, and operates out of Irvine, California. Significant risks are associated with investing in Tarsus's securities, highlighting potential market volatility and dilution effects due to the public offering. Investing in this offering involves risks as outlined in the 'Risk Factors' section of the prospectus supplement.

Document Link: View Document